-
CT has advanced rapidly in recent years, in some cases empowering clinicians to gather huge amounts of data painlessly rather than through invasive procedures. However, there is a tradeoff for the ever-increasing resolution power of the newer scanners: They are picking up a growing number of incidental findings that clinicians must then determine whether to pursue.
-
-
Since it was first introduced in 1984, extracorporeal shock wave lithotripsy (ESWL) has revolutionized the treatment of kidney stone disease and become the treatment of choice for the vast majority of patients.
-
A novel way to treat deep vein thrombosis (DVT) that involves injecting the clot-busting agent alteplase (rTPA) directly into the clots shows promise mid-way through a second study of the approach that is using much lower doses of rTPA than the initial pilot.
-
Cardiogenesis (Irvine, California), a developer of surgical products for cardiac revascularization, reported a scientific presentation that describes the use of the Phoenix delivery system combining transmyocardial revascularization (TMR) with autologous bone marrow derived stem cells.
-
While death rate "report cards" indicated low mortality rates after heart bypass surgery, a review of in-hospital deaths in heart bypass patients at Ontario, Canada hospitals found that one-third might have been prevented, researchers report in Circulation, the journal of the American Heart Association (Dallas).
-
CellCyte Genetics; Feinberg School of Medicine of Northwestern University; Digirad; Johns Hopkins University School of Medicine; IDev Technologies; YMed; Premier Purchasing Partners; GE Healthcare; Siemens Healthcare; Biosense Webster; The Sorin Group; Greatbatch; The Sorin Group
-
Medtronic(Minneapolis) blew analysts' expectations out of the water in the latter part of May when it reported its 4Q financial results, based for the most part on the results of the initial sales of its new Endeavor drug-eluting stent (DES).
-
A study published in a recent issue of the Journal of the American Society of Hypertension demonstrates that the hypertension treatment olmesartan medoxomil was effective in reversing the narrowing of the arteries that occurs in patients with hypertension. The study, Vascular Improvement with Olmesartan medoxomil Study (VIOS), was a one-year, exploratory trial that evaluated the effects of an angiotensin receptor blocker (olmesartan medoxomil) vs. a beta-blocker (atenolol) on vascular function and structure in patients with Stage 1 hypertension, independent of the blood pressure lowering effects of these agents.
-
Diabetes and cardiovascular disease are closely linked, with a high percentage of those with diabetes dying of a cardiovascular illness or event. This is well-recognized, but the relationship between the two diseases is obviously complex.
